What Cistalgina Treats: Main Uses and Benefits

Cistalgina is a medication containing phloroglucinol, generally categorized as an antispasmodic agent. Its primary role is to provide supportive symptomatic relief for symptoms of increased neurological or muscular activity associated with acute or episodic changes. The medication is applied in clinical settings that involve acute or unstable symptom patterns.

Cistalgina (Phloroglucinol) is commonly used to help with spasmodic pain related to functional disorders of the gastrointestinal tract and bile duct. It is also applied in addressing acute, painful spasmodic problems of the urinary tract, such as renal colic, and may assist with the symptomatic management of painful spasmodic gynecological problems, including contexts related to contractions during pregnancy. This supportive relief may help patients cope more steadily with symptom fluctuations.

The medication is relevant for easing symptoms that interfere with daily functioning, and is commonly used during phases when symptoms become more noticeable.

Quick Fact: Relief for Symptoms of increased neurological or muscular activity

Regulatory References

1. Malta Medicines Authority Phloroglucinol ELC package leaflet

Cistalgina (Phloroglucinol) eligibility is strictly defined by regulatory bodies based on contraindications and population-specific limitations.

Contraindications (Must Not Use)

Use is contraindicated and must not occur in individuals with known hypersensitivity to phloroglucinol dihydrate or any excipient in the formulation. The medicine is also strictly prohibited for patients with Phenylketonuria (PKU) due to the presence of aspartame in certain tablets. Furthermore, use is contraindicated for individuals with rare hereditary conditions, including galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, due to the lactose content.

---

Age and Conditional Use

Cistalgina is approved for use in adults and children aged 2 years and older without contraindications. Efficacy is not established for children under two years of age. For reproductive populations, use during pregnancy is restricted and must be considered only when strictly necessary. Use is not recommended while breastfeeding due to a lack of adequate safety data.

Interactions with other medicines and products

Official regulatory information for Cistalgina (Phloroglucinol) defines a specific interaction profile focused on pharmacodynamic antagonism.

Documented Interaction Profile

The primary restriction detailed in regulatory documents concerns co-administration with a specific category of pain relievers.

Category	Regulatory Statement
Medicinal product categories with documented interactions	Major Analgesics (Morphine or Morphine Derivatives)
Mechanistic basis of interactions	Pharmacodynamic antagonism
Interaction-related restrictions	Co-administration is advised to be avoided

Major analgesics, such as morphine and its derivatives, are subject to a pharmacodynamic interaction because they can induce spasms, which directly counteracts the antispasmodic action of Cistalgina. The official regulatory advice requires that this combination be avoided to prevent a reduction in the medicine's intended effect.

Absence of Documented Pharmacokinetic Interactions

Beyond this specific antagonistic effect, authoritative regulatory documents do not explicitly detail interactions involving key metabolic pathways, such as Cytochrome P450 (CYP) enzymes, or drug transporters. Similarly, formal warnings or restrictions regarding interactions with food, alcohol, or herbal products are not specified in the official prescribing information. The profile is limited to the single, specific pharmacodynamic constraint.

Localized Inhibition of Urinary Tract Sensory Nerves

Cistalgina (Phenazopyridine) functions as a localized analgesic agent, primarily operating on the peripheral nervous system. Its mechanism relies on its unique pharmacokinetic profile: after systemic absorption, the compound is rapidly excreted by the kidneys and concentrates in the urine.

This high concentration enables the drug to make direct, topical contact with the mucosal lining of the lower urinary tract (bladder and urethra). The drug interacts with the embedded sensory nerve endings, likely the afferent C-fibers and A-delta fibers, by interfering with the propagation of nerve impulses. This action is characteristic of a local anesthetic, where the transmission of signals is blocked.

Modulation of Somatic Sensory Transduction

By inhibiting the excitability of these peripheral nociceptors, the drug modulates the somatic sensory transduction pathway. This interference results in the inhibition of afferent neural signaling originating from the mucosa. The systemic consequence is the production of localized sensory dampening within the urinary system, which modifies neural inputs that drive rapid micturition reflexes, shaping the drug’s observed physiological effects.

How to Use Cistalgina: Administration Guidelines

Cistalgina, which contains the active ingredient Phenazopyridine hydrochloride, is characterized by specific parameters regarding its administration. The protocol establishes a standardized, high-frequency, short-term course of administration, focusing on the dosage, timing, and duration.

---

Usage Parameters

Usage Entity Category	Instructions
Route and Form	Administration is via the oral route using tablet form.
Dosing Schedule	The standard regimen is three times per day (TID). Adults and children aged 12 and older take 100 mg to 200 mg per dose.
Timing with Food	The medicine is taken after meals or following food intake.
Course Duration	The maximum duration of use is limited to 2 days when administered alongside an antibacterial agent.
Pediatric Dosing	For children aged 6 to 12, the dose is calculated as 12 mg/kg per day, divided into three doses.

---

Special Procedural Constraints

The usage protocol includes procedural constraints that guide proper administration:

• The substance causes a prominent reddish-orange discoloration of the urine.
• Discontinuation is required if a yellowish tinge to the skin or eyes (sclerae) is observed, as this may indicate drug accumulation, necessitating a stop to the administration.

This structured approach standardizes the medicine's use as a brief course that adheres to specific dosing and timing requirements.

Research Evidence / Overview of Studies for Cistalgina

Evidence for use in Interstitial Cystitis/Bladder Pain Syndrome

Cistalgina was studied for its association with outcomes related to symptoms in individuals with Interstitial Cystitis (IC), also referred to as Bladder Pain Syndrome (BPS). Studies conducted during periods of increased symptom activity have examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Research has primarily focused on studies observing responses over defined time intervals and outcomes describing episodic or acute changes.

Findings observed in the studies suggest patterns related to changes measured during the study period, particularly concerning patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning. Findings describe patterns observed in the studies. However, certainty remains low, and the evidence contributes to the broader evidence landscape. The results apply only to the populations studied, and follow-up durations were limited, meaning they may not fully reflect long-term observations.

---

Evidence for use in Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Cistalgina was also evaluated in research contexts involving fluctuating or unstable symptoms associated with men with Chronic Prostatitis (CP) and Chronic Pelvic Pain Syndrome (CPPS), which are conditions characterized by fluctuating or episodic manifestations. Studies monitored outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states. Research was conducted during periods of increased symptom activity to explore short-term symptom changes.

Data show patterns related to how symptoms evolved in the observed populations, and research provides insight into short-term changes in outcomes related to physical discomfort. Findings describe group patterns, not personal outcomes, and evidence is derived from settings with varying symptom burdens. Comparative evidence is lacking, and evidence quality varies across studies, which means the findings must be considered within these research limitations.

---

Long-term Studies and Follow-up

Research focusing on long-term effects of Cistalgina is not fully established. Studies have been monitored over defined time intervals, but there is limited information for long-term outcomes and the durability of any observed response. This section summarizes what is known and unknown about outcomes beyond the immediate study period.

Research has explored whether Cistalgina was associated with changes or stability in symptoms in conditions presenting with cycles of stability and flare-ups over many months or years. While research provides context, findings describe group patterns and do not determine whether an individual will respond similarly over extended durations. Additional research over longer follow-up durations is needed to fully understand any potential extended observations.

---

Evidence in Special Populations

Cistalgina was observed in studies examining symptom intensity or variability in adult populations, but data for certain groups remain insufficient. Research has been limited in exploring the use of Cistalgina in specific populations, such as children or very older adults.

There is also limited published information regarding Cistalgina use in individuals who are pregnant or breastfeeding, or in those with significant or complex comorbid health conditions. Subgroup findings are uncertain, and results apply only to the populations studied. Therefore, the current evidence does not offer specific findings for these groups.

---

What is Still Uncertain About Cistalgina

While Cistalgina was studied for conditions marked by functional limitations and systemic imbalance, key research gaps remain. The evidence quality varies across studies, and findings were mixed in some areas, meaning that not all research reports the same patterns.

The data are still emerging, and there are areas where more research is needed to provide clearer context. Specifically, comparative evidence is lacking, and sample sizes were modest in some studies. Research highlights what is known, but also what is still uncertain about Cistalgina's role in the broader evidence landscape.

Common questions about Cistalgina (FAQ)

Q: Can Cistalgina cause discoloration or staining on clothing or toilet bowls?

Official regulatory information confirms that Cistalgina causes a prominent orange-to-red discoloration of the urine. This substance may also cause staining of fabrics, including clothing and toilet bowls, as well as soft contact lenses.

Q: Why are there limits on the duration for which Cistalgina should be taken?

The standard course is strictly limited to 2 days when taken alongside an antibacterial agent. Regulatory guidance notes that long-term administration of the active ingredient is associated with an increased risk of toxicity, primarily blood disorders, and has been linked to potential carcinogenicity in animal studies.

Q: Are there any known interactions between Cistalgina and blood thinner medications?

The official product information does not detail a major interaction with blood thinners. However, the medicine’s association with a risk of hemolytic anemia (a type of blood disorder) in certain patient groups means the combination may require assessment due to the potential for increased hematologic risk.

Q: Does Cistalgina interact with common over-the-counter pain relievers?

Official information notes a potential concern when Cistalgina is taken with certain pain relievers, such as acetaminophen. The combination may increase the risk or severity of a serious blood condition called methemoglobinemia.

Q: Can individuals who have G6PD deficiency safely take Cistalgina?

Official prescribing information indicates that Cistalgina is contraindicated for individuals with G6PD deficiency. This specific blood condition significantly increases the risk of hemolysis (the breakdown of red blood cells) when the medicine is taken.

Q: Is Cistalgina used for treating pain related to medical procedures or catheter use?

Official drug information indicates that Cistalgina is used to relieve discomfort and pain from lower urinary tract irritation. This includes irritation resulting from infections, surgery, as well as from the use of endoscopic procedures or catheters.

Q: Can Cistalgina affect the color of my soft contact lenses?

Official information states that Cistalgina may stain soft contact lenses. Official guidance notes that the use of soft lenses during treatment may be avoided because the staining may be permanent.

Q: How quickly do the coloring effects of Cistalgina disappear after stopping the medicine?

The reddish-orange urine color is an expected and unavoidable effect of the medicine. Official patient information indicates that the color is expected to go away after discontinuing the medicine. A precise timeline for the disappearance of the coloring is not usually specified on the product label.

Q: How is Cistalgina different from general, non-urinary pain relief medications?

Cistalgina is classified as a local anesthetic that provides relief by acting directly on the sensory nerve endings in the lining of the urinary tract. Unlike general pain relievers that act systemically, this medicine's action is localized to the urinary mucosa.

Q: What is the relationship between Cistalgina and a blood condition called methemoglobinemia?

Methemoglobinemia is a serious condition where the blood's ability to carry oxygen is reduced. According to regulatory documents, this condition is associated with Cistalgina use in cases of overdose, high levels in the bloodstream, or existing impaired kidney function.

Q: Can Cistalgina be used if I have been previously diagnosed with anemia?

Official safety information indicates that the medicine can potentially cause a condition called hemolytic anemia in certain patients. For this reason, those with pre-existing blood disorders may be at an increased risk.

Q: What happens if Cistalgina is accidentally taken for longer than the recommended two days?

Official prescribing information indicates that use for more than two days may be associated with drug accumulation in the body. This accumulation is often signaled by a yellowish tinge to the skin or eyes, and its observation is an indication that discontinuance is required due to increased risk of toxicity.

Q: Does Cistalgina interact with medicines for diabetes or high blood pressure?

Official regulatory documents do not specify interactions with high blood pressure medicines. However, they do note that this medicine may cause false test results for certain urine sugar tests used by diabetic patients.

Official Storage Conditions

Cistalgina, which contains Phenazopyridine hydrochloride, must be stored within the temperature range defined as Controlled Room Temperature, specifically 20 C to 25 C (68 F to 77 F). The medication must be protected from excess heat and moisture to maintain its stability. Tablets must be stored in a tight container and dispensed with a child-resistant closure to comply with official packaging requirements.

Child Safety and Disposal Rules

It is mandatory that the medicine be kept out of the sight and reach of children. For disposal, unused or expired product must be discarded according to local and federal regulations. This product is not to be flushed down the toilet; safe disposal is typically advised through a drug take-back program or by sealing the medication in household trash.